[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Dohil et al., 2003 - Google Patents

The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine

Dohil et al., 2003

View PDF
Document ID
6900330133896758407
Author
Dohil R
Newbury R
Sellers Z
Deutsch R
Schneider J
Publication year
Publication venue
The Journal of pediatrics

External Links

Snippet

Objectives Cysteamine prevents organ damage in children with cystinosis, but may cause gastrointestinal (GI) symptoms. In this study we evaluated the nature of GI disease, and the value of omeprazole in controlling GI symptoms in these children. Study design Upper GI …
Continue reading at cystinosis.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Dohil et al. The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine
JP6178657B2 (en) Compositions and methods for binding acetaldehyde in the stomach
Zentilin et al. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH‐metry
Pilotto et al. The effect ofHelicobacter pyloriinfection on NSAID-related gastroduodenal damage in the elderly
Casellas et al. Hydrogen breath test with glucose in exocrine pancreatic insufficiency
Lanspa et al. Pathogenesis of steatorrhea in primary biliary cirrhosis
Dohil et al. Understanding intestinal cysteamine bitartrate absorption
Bendz et al. Kidney function in an unselected lithium population: A cross‐sectional study
Snider et al. Eruptive keratoacanthoma with an internal malignant neoplasm
Gan et al. Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects
Dalldorf et al. Incidence of gastric ulcer in albino rats fed diets deficient in vitamin B (B1)
Hirschowitz et al. Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger-Ellison syndrome
Piena-Spoel et al. “Gut-feeling” or evidence-based approaches in the evaluation and treatment of human short-bowel syndrome
Yuldashova Ways To Increase The Efficiency Of Ferrotherapy In Iron Deficiency Anemia Taking Into Account The Presence Of Helicobacteriosis
Bove et al. Effects of dietary nitrate on oesophageal motor function and gastro-oesophageal acid exposure in healthy volunteers and reflux patients
Akiyama et al. Esophageal reconstruction for stenosis due to diffuse scleroderma: Utilizing blunt dissection of esophagus
Golwalla et al. Golwalla's Medicine for Students: A Reference Book for the Family Physician
Herath et al. Eosinophilic Oesophagitis: A False Negative Result on Biopsy
Szafran et al. The effect of 2-deoxy-D-glucose and insulin stimulation on the secretion of gastric lipase
US20230108730A1 (en) Bienzymatic biosensor for the detection of lactulose in blood
Namiot et al. Vitamin C does not improve the efficacy of Helicobacter pylori eradication in smokers
Pontes et al. How oral infections can influence chronic kidney disease–a review of the literature
Kurahashi et al. Starch digestion by parotid amylase in the gastrointestinal tract of rats with pancreatitis
Thomson et al. Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients
EP0987022B1 (en) Conagenin for the treatment of ulcerous colitis and/or crohn's disease